Massive study probes cancer risk of common diabetes drug
NCT ID NCT02695121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study analyzed health records from over 2 million people with type 2 diabetes to see if those taking dapagliflozin had a different risk of breast or bladder cancer compared to those on other diabetes medications. Researchers tracked cancer diagnoses for up to 12 years. The goal is to better understand the long-term safety of dapagliflozin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin
What this could lead to
If this study finds no increased cancer risk, it could reassure patients and doctors that dapagliflozin is safe to use for type 2 diabetes.
What could go wrong
This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may be influenced by other factors like patient health or lifestyle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Wilmington, Delaware, United States
-
Research Site
Washington D.C., District of Columbia, United States
-
Research Site
Utrecht, Netherlands
-
Research Site
London, United Kingdom